Dentsply Sirona INC

Dentsply Sirona announced the appointment of John Fortson as its new Executive Vice President and Chief Financial Officer, effective July 20, 2026.

DENTSPLY SIRONA Inc. reports the successful election of twelve directors and approval of key incentive plans at its 2026 Annual Meeting.

DENTSPLY SIRONA Inc. announced its first fiscal quarter 2026 financial results, reporting net sales of $880 million and reiterating its full-year outlook.

Dentsply Sirona announced Q4 2025 net sales growth and adjusted EPS, alongside a restructuring plan, dividend elimination, and a 2026 outlook.

Dentsply Sirona expands its Board of Directors with two new financial and operational experts to enhance strategic oversight for its Return-to-Growth plan.

Dentsply Sirona and Patterson Dental have renewed their U.S. dental technology distribution agreement, aiming to accelerate growth and expand access to integrated solutions.

DENTSPLY SIRONA Inc. reported a net loss of $10 million for the first quarter of 2026, a significant shift from the prior year's profit, driven by increased restructuring costs and lower gross profit margins.

Dentsply Sirona reported a net loss of $427 million for Q3 2025, driven by lower sales volumes, significant goodwill and intangible asset impairments, and increased tax provision, despite some operational improvements.

Dentsply Sirona Inc. reported a significant net loss in Q2 2025, driven by substantial goodwill and intangible asset impairments, alongside declining net sales and cash flow from operations.

Dentsply Sirona's Q1 2025 results reveal a decrease in net sales and organic sales, influenced by strategic decisions and macroeconomic headwinds, despite improvements in certain segments.

Dentsply Sirona's Q3 2024 results were significantly impacted by goodwill impairment charges and the voluntary suspension of its Byte aligner system.

Dentsply Sirona's second-quarter results show a net loss, impacted by restructuring costs and market pressures, despite some growth in specific segments.

Dentsply Sirona reported a significant net loss of $598 million for 2025, a 3.0% decrease in net sales, and eliminated its quarterly dividend, signaling ongoing operational and financial challenges.

DENTSPLY SIRONA Inc. reports a net loss for 2024, impacted by significant goodwill and intangible asset impairment charges, despite increased cash from operations.

Dentsply Sirona outlines its non-employee director compensation policy, including cash retainers and equity awards, while also providing a comprehensive overview of its 2023 financial results and business operations.

DENTSPLY SIRONA Inc. director Jonathan Jay Mazelsky acquired phantom stock units valued at $10.56 per share, representing a total of 2,841.8303 units.

DENTSPLY SIRONA Inc. reports a Form 4 filing detailing a stock purchase by Director Jonathan Jay Mazelsky.

Director Clyde Hosein acquired 6,500 shares of Dentsply Sirona common stock at a price of $9.985 per share.

DENTSPLY SIRONA Director Brian P. McKeon acquired 10,000 shares of common stock through a trust, signaling confidence.

DENTSPLY SIRONA Inc. reports a significant stock purchase by Director Brian T. Gladden, acquiring over 9,900 shares.

Dentsply Sirona Director Jonathan Jay Mazelsky reported the acquisition of 10,000 shares of common stock.

Dentsply Sirona's 2026 proxy statement outlines the upcoming annual meeting agenda, including director elections, executive compensation approval, and a request to increase shares under the 2024 Omnibus Incentive Plan.

Dentsply Sirona issues a supplement to its proxy statement to correct a typographical error regarding the number of outstanding shares of common stock as of March 24, 2025.

Dentsply Sirona has filed a definitive proxy statement with the Securities and Exchange Commission.

Dentsply Sirona is asking stockholders to approve an amendment to its 2024 Omnibus Incentive Plan to increase the number of shares available for issuance by 11,260,000.

Dentsply Sirona has filed a definitive proxy statement with the SEC regarding its upcoming shareholder meeting.

Dentsply Sirona sets date for its 2024 Annual Meeting of Stockholders, outlining key proposals and voting procedures.

Vanguard Capital Management has filed a Schedule 13G reporting a 5.27% beneficial ownership stake in DENTSPLY SIRONA Inc.

Vanguard Portfolio Management has reported beneficial ownership of 10,724,505 shares, representing 5.36% of DENTSPLY SIRONA Inc.'s common stock.

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership of DENTSPLY SIRONA Inc. common stock due to an internal realignment.

Southpoint Master Fund and affiliated entities have reported a 5.0% passive ownership stake in Dentsply Sirona Inc., holding 10 million shares.

AQR Capital Management, LLC and its parent company have disclosed a 2.45% beneficial ownership stake in DENTSPLY SIRONA Inc. common stock.

T. Rowe Price Associates, Inc. filed an amended Schedule 13G, reporting a 0.1% beneficial ownership stake in DENTSPLY SIRONA INC.